Skip to main content
OpenTrials
Completed

NCT Number: NCT06639555

Initial Clinical and CBCT Outcomes of Enamel Matrix Derivative-Based Regenerative Therapy in Vertical Bone Defects

Study of the effectiveness of the application of regenerative therapy with autogenous, platelet-rich plasma in vertical defects Investigation of the effectiveness of the application of regenerative therapy with enamel matrix derivatives in vertical bone defects Study of the effectiveness of the application of guided tissue regeneration in vertical bone defects with Barrier membrane and Barrier membrane and autogenous platelet-rich plasma

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vertical Alveolar Bone Loss

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medical University - Varna

Varna, 9000, Bulgaria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • good oral hygiene
  • written informed consent
  • age
  • no systemic diseases

Exclusion criteria

  • smokers
  • horizontal bone loss
  • untreated periodontium disease

Treatment and study plan

PRP( platelet rich plasma)

Procedure

regenerative therapy with PRP for vertical bone defects

EMD (Enamel Matrix Derivative)

Procedure

regenerative therapy with EMD for vertical bone defects

Guided Tissue Regeneration (barrier membrane)

Procedure

guided tissue regeneration with barrier membrane alone for vertical bone defects

Guided Tissue Regeneration(barrier membrane and PRP)

Procedure

guided tissue regeneration with barrier membrane and PRP for vertical bone defects

Primary outcomes

  1. Probing depth in mm

    Time frame: 6 months

  2. Level of Margo Gingivalis in mm

    Time frame: 6 months

  3. Clinical attachment level in mm

    Time frame: 6 months

  4. The distance from the ECJ to the base of the bone defect in mm

    Time frame: 6 months

  5. The distance from the ECJ to the apex of the bone defect in mm

    Time frame: 6 months

  6. The width of the bone defect in mm

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Tsvetalina Gerova-Vatsova

Other

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 15, 2024
Registry last updated
Oct 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.